In first-opinion companion animal practice, methoxyflurane veterinary-grade API is consumed in the highest volume as a single-use inhaler solution for canine and feline trauma analgesia, rather than as a tablet, capsule, powder, granule, premix, or injectable format. The terminal fill composition is 99.99% w/w methoxyflurane with 0.01% w/w butylated hydroxytoluene in the Penthrane/Penthrox-type inhaler; alternative veterinary inhaler constructs use undiluted methoxyflurane at 100% w/w. The nominal reservoir fill is 3.00 mL, equivalent to approximately 4.26 g at the liquid density of 1.42 g/mL at 20 °C, and the applicable manufacturing authority is the current good manufacturing practice framework in 21 CFR Parts 210 and 211, with drug substance identity and assay controlled by the Ph. Eur. methoxyflurane monograph, residual solvent limits by ICH Q3C, and inhaler component biocompatibility by ISO 10993-1:2018. Downstream production of the terminal single-use inhaler typically proceeds on a continuous filling line in which bulk API is received in fluoropolymer-lined drums, transferred under filtered nitrogen, held in a jacketed pressure vessel below 20 °C to suppress evaporative loss, passed through a 0.22 µm hydrophobic membrane, metered by calibrated ceramic piston pumps, filled into the inhaler reservoir, sealed by a crimped aluminium ferrule, checkweighed to confirm the 3 mL target, leak-tested by pressure-decay or helium mass spectrometry, and visually inspected. Terminal product type is a single-use handheld inhaler delivering approximately 0.1–0.5% v/v inspired methoxyflurane depending on ambient temperature and tidal volume, with the clinical dose envelope limited to 6 mL per patient-day and 15 mL per week because methoxyflurane metabolism generates inorganic fluoride and oxalate with dose-dependent nephrotoxicity. This dosage form is used in dogs and cats for procedural trauma analgesia before wound repair, fracture immobilisation, abscess drainage, and transfer to surgery; use in food-producing animals is excluded in jurisdictions where maximum residue limits have not been established.

Bulk Vapouriser Refill Bottle Filling and Fluoride Impurity Control

Bulk methoxyflurane for conventional veterinary anaesthesia vaporisers is filled into small-volume amber glass or fluoropolymer-coated bottles as a refill product, and the terminal product type is a pour-bottle or keyed filler bottle that mates with agent-specific vapouriser filling ports. The formulation addition ratio in this segment is 100% w/w methoxyflurane API; no dilution solvent, stabiliser, propellant, or co-solvent is added in the refill-bottle product. Compliance anchors include 21 CFR 211.94 for container closure system design, Ph. Eur. 2.2.28 gas chromatography for purity and related substance determination, ICH Q3C for residual methanol limits—methanol is assigned a Class 2 limit of 3,000 ppm under Option 1—and ASTM D4169-22 for distribution-cycle shock and vibration testing. Downstream production process is different from the inhaler line because the bottle must be filled to a gross fill weight that accommodates vapouriser keyed fillers without headspace overpressure; the filling train uses gravimetric weighing to maintain fill mass within the target tolerance, inert-gas blanketing to keep water uptake below the monograph limit, and a two-stage crimping or screw-cap torque station. In-process controls include gas chromatographic assay at the start, middle, and end of the fill run; Karl Fischer water determination; visual inspection for glass particles or surface pitting; and leak testing of the sealed bottle by vacuum decay. The critical impurity profile of methoxyflurane is driven by oxidative and photolytic degradation, and the refill-bottle specification therefore limits headspace oxygen, controls storage at controlled room temperature, and requires protection from light. Fluoride impurity in the API is not a direct release limit but becomes a toxicologic trigger after hepatic oxidative dechlorination in the patient; the bulk bottle label and certificate of analysis must therefore align with the intended vapouriser administration protocol.

When 0.29% v/v Canine MAC Dictates Vapouriser Output Calibration

The calibration envelope for methoxyflurane vapourisers is narrower than for isoflurane because the minimum alveolar concentration in dogs is approximately 0.29% v/v and in cats approximately 0.23% v/v, so a vapouriser output error of ±10% shifts maintenance depth by a clinically relevant fraction of one MAC. The terminal product type is a precision agent-specific anaesthesia workstation or free-standing vapouriser with temperature-compensated bypass flow and wick-saturated agent reservoir. Formulation addition ratio in this downstream sector is not a chemical addition but the required vapouriser fill volume set against the reservoir capacity; methoxyflurane is filled to the maximum marker at room temperature, and refilling is performed only after the vapouriser is switched off and at ambient temperature because the high blood/gas partition coefficient of 12–15 slows equilibration and because overfilling can carry liquid droplets into the bypass chamber. Downstream production of the calibrated device involves verifying output at 0.1%, 0.25%, 0.5%, and 0.75% v/v dial settings across a temperature range of 15–35 °C using an anaesthetic gas analyser calibrated according to ISO 80601-2-13:2022, with corrections for carrier gas composition and backpressure. Compliance anchor for the analyser and vapouriser is ISO 80601-2-13:2022 for anaesthetic workstation safety and performance, supplemented by the anaesthetic agent batch certificate for the methoxyflurane used in the validation run. The practical boundary condition is that methoxyflurane is highly soluble in rubber and many plastic circuit components; therefore output verification must be performed after prolonged equilibration of the circuit, and circuit material must be specified as low-absorption polypropylene or high-density polyethylene to minimise volatile agent scavenging. Published data for the specific interaction of methoxyflurane with some low-volume circle-system materials is limited, and the calibration protocol must include a baseline output curve using the intended circuit material.

In compounding pharmacies serving zoological institutions and small-mammal referral practices, methoxyflurane is repackaged into unit-dose syringes or adapter reservoirs for species in which the standard 3 mL inhaler dose is not appropriate, such as small felids, procyonids, and selected avian patients where volatile anaesthetic induction may be considered but species-specific outcome data are limited. The addition ratio in this segment is 100% w/w methoxyflurane transferred as-is; dilution with aqueous solvents is not performed because the solubility of methoxyflurane in water is low and the resulting product would separate. The governing compliance texts are USP Chapter 795 for nonsterile compounding, USP Chapter 800 for hazardous drug containment, and local veterinary pharmacy board regulations; because methoxyflurane is volatile, the compounding process proceeds inside an exhausted isolator or fume hood with continuous gas monitoring. Downstream production of the unit-dose product involves drawing methoxyflurane from a sealed bulk bottle through an activated-carbon vent adapter, filling dark amber glass or fluoropolymer syringes to volumes of 0.5–3.0 mL, sealing with Luer caps, labelling with beyond-use date assigned from USP Chapter 795, and storing at controlled room temperature. Terminal product type is an extemporaneously prepared unit-dose inhalation reservoir for veterinary use; the administered dose is titrated by observed effect rather than by a fixed dial percentage because the delivery device is often a low-dead-space paediatric circuit or a modified Ayre's T-piece. Published data for this specific configuration is limited, and dose-finding should be based on institutional anaesthesia records rather than small-animal label dosing.

Analytical Reference Standards and Purge-and-Trap Gas Chromatography Calibration

Reference-standard methoxyflurane is a low-volume but analytically demanding downstream category, in which the terminal product type is a certified reference material or calibration solution used to validate gas chromatographic, headspace, or purge-and-trap mass spectrometric methods. The formulation addition ratio for the preparation of working standards is typically 1,000 µg/mL methoxyflurane in purge-and-trap-grade methanol, with subsequent dilution to 10, 50, and 100 µg/mL calibration points; neat standards may be supplied in flame-sealed glass ampoules at ≥99.0% w/w certified purity. Compliance anchor for this downstream segment is ISO/IEC 17025:2017 for testing and calibration laboratories and ISO 17034:2016 for reference material producers, with traceability to the Ph. Eur. or USP methoxyflurane monograph. Downstream production of the calibration solution is performed under gravimetric control: neat methoxyflurane is transferred via gas-tight syringe into pre-weighed vials containing septum-sealed methanol, the mass is recorded to 0.1 mg, and the solution is homogenised without headspace exchange at 4 °C. Storage requirements are stringent because methoxyflurane slowly degrades under ultraviolet light; amber borosilicate vials and nitrogen-purged headspace are used, and stock solutions are stored at −20 °C for no more than the period validated by stability testing. The terminal product is not administered to patients but controls method linearity, limit of detection, limit of quantitation, and recovery in environmental air monitoring, inhalation device output testing, and toxicokinetic studies.

What Excludes Methoxyflurane from Tablets, Capsules, Injections, Powders, Granules, and Premix Formats?

Because methoxyflurane is a volatile liquid at room temperature with a boiling point of 104.8 °C and a vapour pressure of 22.5 mmHg at 20 °C, oral solid dosage forms such as tablets, capsules, powders, granules, and premix blends are physically incompatible with the API and are not commercialised as methoxyflurane drug products. The same exclusion applies to aqueous injectable solutions and oil-in-water emulsions: methoxyflurane has low water solubility, would undergo phase separation, and would expose the patient to a bolus of highly lipid-soluble anaesthetic with an unacceptable risk of cardiac and central nervous system toxicity; no pharmacopoeial monograph supports these routes. The compliance anchor for this exclusion is the Ph. Eur. methoxyflurane monograph, which defines the drug substance as a liquid for inhalation, together with 21 CFR 211.67 equipment cleaning and ICH Q3C solvent limitations that make solid-form manufacturing impractical. Formulation addition ratio in any such attempt would require conversion of the API to a solid adsorption complex or microencapsulated product, and no published data for this specific configuration is available; the only commercially relevant addition ratio remains 100% w/w liquid methoxyflurane with or without 0.01% w/w butylated hydroxytoluene. Downstream production process for these excluded formats would require spray-drying or extrusion-spheronisation at temperatures well above the API boiling point, causing evaporative loss and occupational exposure above generally accepted time-weighted average limits; the terminal product type is therefore not manufactured. The practical consequence for formulation development is that methoxyflurane veterinary API is allocated exclusively to inhalation solution and vapour delivery systems.